10:01 AM
 | 
Dec 20, 2017
 |  BC Innovations  |  Translation in Brief

Diabetes hits a checkpoint

Cranking up PD-L1 on HSPCs for autoimmune disease

A Science Translational Medicine study suggests increasing PD-L1 levels in hematopoietic stem and progenitor cells (HSPCs) could help treat Type I diabetes. Additionally, the authors think transplants of HSPCs modified with PD-L1-boosting gene therapies or compounds could be deployed to treat a wide range of autoimmune diseases, and the biology controlling PD-L1 expression in HSPCs could be exploited to treat cancer.

Author Paolo Fiorina told BioCentury that HSPCs were known to tamp down inflammation in graft-versus-host disease (GvHD), and that his group had previously shown HSPC-mediated immune suppression required PD-L1 expression by the cells. Fiorina is an assistant professor of pediatrics at Harvard...

Read the full 493 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >